01/16/2025
11:15 PM | Inhibikase Therapeutics (Filer)
| Form EFFECT | |
01/10/2025
3:37 PM | Inhibikase Therapeutics (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
01/07/2025
5:39 PM | Freeman Roy Lester (Reporting)
Inhibikase Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/07/2025
5:43 PM | Inhibikase Therapeutics (Issuer)
Lees-Rolfe Garth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/07/2025
5:47 PM | Inhibikase Therapeutics (Issuer)
Werner Milton H. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/07/2025
5:38 PM | BERMAN DENNIS N (Reporting)
Inhibikase Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/06/2025
5:06 AM | Inhibikase Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/05/2024
11:15 PM | Inhibikase Therapeutics (Filer)
| Form EFFECT | |
12/05/2024
3:47 PM | Inhibikase Therapeutics (Filer)
| Form 424B3 | |
12/05/2024
3:50 PM | Inhibikase Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/03/2024
5:24 AM | Inhibikase Therapeutics (Filer)
| Form S-3/A | |
|
11/18/2024
3:49 PM | Inhibikase Therapeutics (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
11/14/2024
7:30 AM | Inhibikase Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
11/08/2024
3:07 PM | Inhibikase Therapeutics (Filer)
| Form PRE 14A | |
10/28/2024
4:26 PM | Inhibikase Therapeutics (Subject)
SP IKT Holdings LLC (Filed by)
| Form SC 13G | |
10/28/2024
3:00 PM | Inhibikase Therapeutics (Subject)
Soleus Private Equity Fund III, L.P. (Filed by)
| Form SC 13G | |
10/25/2024
4:52 PM | Inhibikase Therapeutics (Issuer)
Sands Capital Life Sciences Pulse Fund II, L.P. (Reporting)
Sands Capital Ventures, LLC (Reporting)
SANDS FRANK M. (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
10/25/2024
4:50 PM | Inhibikase Therapeutics (Subject)
Sands Capital Life Sciences Pulse Fund II, L.P. (Filed by)
| Form SC 13G | |
10/23/2024
6:58 PM | Canner David (Reporting)
Inhibikase Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/23/2024
6:35 PM | Bellini Roberto (Reporting)
Inhibikase Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
10/23/2024
6:36 PM | Inhibikase Therapeutics (Issuer)
Munshi Amit (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
10/23/2024
6:38 PM | Canner David (Reporting)
Inhibikase Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
10/23/2024
6:40 PM | Inhibikase Therapeutics (Issuer)
Kush Arvind (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
10/23/2024
6:43 PM | Inhibikase Therapeutics (Issuer)
Munshi Amit (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/23/2024
6:49 PM | Inhibikase Therapeutics (Issuer)
Kush Arvind (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/23/2024
6:53 PM | Bellini Roberto (Reporting)
Inhibikase Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/22/2024
3:15 PM | Inhibikase Therapeutics (Subject)
PERCEPTIVE ADVISORS LLC (Filed by)
| Form SC 13G | |
10/21/2024
8:13 PM | Inhibikase Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/17/2024
6:00 PM | Fairmount Funds Management LLC (Filed by)
Inhibikase Therapeutics (Subject)
| Form SC 13G | |
10/17/2024
3:05 PM | COMMODORE CAPITAL LP (Filed by)
Inhibikase Therapeutics (Subject)
| Form SC 13G | |
10/10/2024
4:31 PM | Inhibikase Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/09/2024
7:40 AM | Inhibikase Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/05/2024
8:21 PM | Inhibikase Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/18/2024
4:23 PM | Dion Gisele (Reporting)
Inhibikase Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/18/2024
4:27 PM | GRINT PAUL C (Reporting)
Inhibikase Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/18/2024
4:18 PM | Freeman Roy Lester (Reporting)
Inhibikase Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/18/2024
4:20 PM | BERMAN DENNIS N (Reporting)
Inhibikase Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/26/2024
8:25 PM | Inhibikase Therapeutics (Filer)
| Form 424B3 | |
06/26/2024
11:15 PM | Inhibikase Therapeutics (Filer)
| Form EFFECT | |
06/21/2024
3:30 PM | Inhibikase Therapeutics (Filer)
| Form DEFA14A | |
06/20/2024
5:06 PM | Inhibikase Therapeutics (Filer)
| Form DEF 14A | |
Bill Gates’ is about to mint millionaires (again) with Stargate. (Ad) This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS.
But what’s even more unbelievable?
I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket. Click here and I’ll tell you everything you need to know. |
06/18/2024
4:27 PM | Inhibikase Therapeutics (Filer)
| Form S-1
Registration statement under Securities Act of 1933 | |
06/10/2024
3:20 PM | Inhibikase Therapeutics (Filer)
| Form PRE 14A | |
05/22/2024
7:55 AM | Inhibikase Therapeutics (Filer)
| Form 424B5 | |
05/20/2024
7:55 AM | Inhibikase Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/20/2024
6:09 AM | Inhibikase Therapeutics (Filer)
| Form 424B5 | |
05/15/2024
6:56 AM | Inhibikase Therapeutics (Filer)
| Form RW | |
05/09/2024
1:41 PM | Inhibikase Therapeutics (Filer)
| Form S-1/A | |
04/30/2024
7:17 AM | Inhibikase Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/26/2024
3:20 PM | Inhibikase Therapeutics (Filer)
| Form ARS | |
04/26/2024
3:15 PM | Inhibikase Therapeutics (Filer)
| Form DEF 14A | |
04/25/2024
3:29 PM | Inhibikase Therapeutics (Filer)
| Form S-1/A | |
04/19/2024
4:14 PM | Inhibikase Therapeutics (Filer)
| Form S-1
Registration statement under Securities Act of 1933 | |
04/18/2024
8:46 PM | Inhibikase Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/02/2024
4:12 PM | Inhibikase Therapeutics (Filer)
| Form 8-K/A | |
04/02/2024
4:12 PM | Inhibikase Therapeutics (Issuer)
Lees-Rolfe Garth (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
04/02/2024
4:14 PM | Inhibikase Therapeutics (Issuer)
Lees-Rolfe Garth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/07/2024
6:59 AM | Inhibikase Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/01/2024
3:49 PM | Inhibikase Therapeutics (Filer)
| Form 424B5 | |
Free IKT Stock Alerts